Halt Medical Inc. - Acessa Procedure

Halt Medical Inc. develops the Acessa Procedure, a minimally invasive, outpatient treatment addressing symptomatic uterine fibroids. This advanced technology employs controlled radiofrequency energy to induce coagulative necrosis of fibroid tissue, which then softens and shrinks over time, alleviating symptoms without requiring uterine suturing. The procedure integrates simultaneous laparoscopic camera and ultrasound views, optimizing imaging for precise treatment of fibroids regardless of their location, including those within uterine walls.

The company was founded in 2004 by Bruce Lee, driven by an insight into the need for less invasive and more effective treatment options for common gynecological conditions. Lee envisioned a solution that would offer women a uterine-sparing alternative to traditional surgical interventions, improving recovery times and reducing discomfort associated with fibroid removal. This foundational principle guided the development of its core therapeutic system.

Women suffering from symptomatic uterine fibroids are the primary beneficiaries of the Acessa Procedure, experiencing minimal post-procedure discomfort and a swift return to daily activities. Halt Medical Inc.'s long-term vision centers on improving women's health outcomes by providing innovative, gentler treatments that preserve uterine function and enhance quality of life, continually expanding access to its beneficial therapies.

High-Level Overview

Halt Medical, Inc. develops the Acessa System, a minimally invasive medical device for treating symptomatic uterine fibroids through laparoscopic radiofrequency ablation.[1][2] The Acessa Procedure targets fibroids with heat to shrink and soften them, offering a non-hormonal, uterine-sparing alternative to hysterectomy or myomectomy, primarily serving women experiencing heavy bleeding, pain, or pressure from fibroids.[1][2][3] It solves the problem of fibroid symptoms affecting up to 77% of women by enabling outpatient treatment with quick recovery—patients often return to work in 4-5 days—while preserving fertility and avoiding major surgery.[2]

The company, based in Brentwood, California, has raised $66.8 million in total funding across three rounds, with the most recent at $63.3 million, indicating strong investor interest in its growth potential despite limited recent public news.[1]

Origin Story

Halt Medical, Inc. emerged in the medical device space focused on women's health, with early milestones including the first commercial use of the Acessa Procedure in 2012, performed by Dr. Berman at Berry Surgery Center in Farmington Hills, Michigan, for uterine fibroid treatment.[4] The idea stemmed from addressing gaps in fibroid care, developing a laparoscopic technology that uses ultrasound-guided radiofrequency energy to ablate fibroids precisely.[1][2][3]

Founders and exact founding year details are not specified in available sources, but the company's evolution centered on clinical validation and commercialization of the Acessa System, culminating in an acquisition agreement announced via PR Newswire, where Halt Medical agreed to be acquired, likely to scale its uterine-sparing innovation.[5]

Core Differentiators

• Minimally Invasive Approach: Uses three small abdominal incisions for laparoscopy, with ultrasound to locate fibroids, followed by targeted radiofrequency ablation that shrinks fibroids over time without hormones or uterine removal.[2][3]
• Patient Outcomes: Clinical data shows rapid recovery (4-5 days to work), symptom relief starting in 3 months and improving over 12 months, with fibroids softening from "baseball" firmness to "marshmallow."[2]
• Safety and Efficacy: Positioned as a safer alternative to hysterectomy/myomectomy, preserving the uterus and fertility; first commercial use validated its real-world application.[3][4]
• Commercial Maturity: Backed by $66.8M funding, with the Acessa System now integrated post-acquisition by Acessa Health Inc., enhancing market reach.[1][3]

Role in the Broader Tech Landscape

Halt Medical rides the trend of minimally invasive gynecology, amid rising demand for uterine-sparing fibroid treatments as awareness grows—77% lifetime prevalence drives market expansion.[2] Timing aligns with advances in radiofrequency ablation and laparoscopy, reducing surgical risks in women's health, where fibroids impact quality of life for millions.[1][2]

Market forces like aging populations, fertility preservation priorities, and shifts from invasive surgeries favor Acessa, influencing the ecosystem by setting a new standard for outpatient fibroid care and inspiring similar device innovations.[1][3]

Quick Take & Future Outlook

Post-acquisition by Acessa Health Inc., Halt Medical's Acessa System is poised for wider adoption through expanded distribution and clinical integration.[3] Trends like personalized women's health tech and value-based care will shape its path, potentially boosting procedure volumes as data on long-term outcomes accumulates. Its influence may evolve by normalizing ablation as first-line therapy, reducing hysterectomy rates and enhancing patient-centered gynecology—building on its funding-fueled foundation to redefine fibroid management.[1][2][5]